Scientific Library of Tomsk State University

   E-catalog        

Normal view MARC view

Deconvoluting hepatic processing of carbon nanotubes S. Alidori, R. L. Bowman, D. Yarilin [et.al.]

Contributor(s): Alidori, Simone | Yarilin, Dmitry | Romin, Yevgeniy | Barlas, Afsar | Mulvey, J. Justin | Fujisawa, Sho | Xu, Ke | Ruggiero, Alessandro | Riabov, Vladimir B | Bowman, Robert L | Thorek, Daniel L. J | Ulmert, Hans David S | Brea, Elliott J | Behling, Katja | Kzhyshkowska, Julia G | Manova-Todorova, Katia | Scheinberg, David A | McDevitt, Michael RMaterial type: ArticleArticleSubject(s): углеродные нанотрубки | печень | применение в медицинеGenre/Form: статьи в журналах Online resources: Click here to access online In: Nature communications Vol. 7. P. 12343 (1-11)Abstract: Single-wall carbon nanotubes present unique opportunities for drug delivery, but have not advanced into the clinic. Differential nanotube accretion and clearance from critical organs have been observed, but the mechanism not fully elucidated. The liver has a complex cellular composition that regulates a range of metabolic functions and coincidently accumulates most particulate drugs. Here we provide the unexpected details of hepatic processing of covalently functionalized nanotubes including receptor-mediated endocytosis, cellular trafficking and biliary elimination. Ammonium-functionalized fibrillar nanocarbon is found to preferentially localize in the fenestrated sinusoidal endothelium of the liver but not resident macrophages. Stabilin receptors mediate the endocytic clearance of nanotubes. Biocompatibility is evidenced by the absence of cell death and no immune cell infiltration. Towards clinical application of this platform, nanotubes were evaluated for the first time in non-human primates. The pharmacologic profile in cynomolgus monkeys is equivalent to what was reported in mice and suggests that nanotubes should behave similarly in humans.
Tags from this library: No tags from this library for this title. Log in to add tags.
No physical items for this record

Библиогр.: 59 назв.

Single-wall carbon nanotubes present unique opportunities for drug delivery, but have not advanced into the clinic. Differential nanotube accretion and clearance from critical organs have been observed, but the mechanism not fully elucidated. The liver has a complex cellular composition that regulates a range of metabolic functions and coincidently accumulates most particulate drugs. Here we provide the unexpected details of hepatic processing of covalently functionalized nanotubes including receptor-mediated endocytosis, cellular trafficking and biliary elimination. Ammonium-functionalized fibrillar nanocarbon is found to preferentially localize in the fenestrated sinusoidal endothelium of the liver but not resident macrophages. Stabilin receptors mediate the endocytic clearance of nanotubes. Biocompatibility is evidenced by the absence of cell death and no immune cell infiltration. Towards clinical application of this platform, nanotubes were evaluated for the first time in non-human primates. The pharmacologic profile in cynomolgus monkeys is equivalent to what was reported in mice and suggests that nanotubes should behave similarly in humans.

There are no comments on this title.

to post a comment.
Share